Overland Pharmaceuticals, backed by Hillhouse Capital, is building a fully integrated biopharma company with a mission to bring innovative medicines to underserved patients in Asia and around the world.
By leveraging our resources, global network, and local expertise across the biopharma ecosystem in Asia, Overland is establishing a portfolio of differentiated therapeutic candidates in a few carefully selected therapeutic areas.
Through formative R&D partnerships, Overland will move forward the development and commercialization of the most promising advances in medicine.
Through strategically engineered alliances, Overland focuses on innovative therapeutic programs and cutting-edge technology platforms to deliver maximum value to all stakeholders with the ultimate goal of serving patients around the world.
Overland’s flexible business approach and ability to architect differing partnership models (e.g. joint-venture, licensing, and equity investment deal structures), coupled with deep local expertise and a strong track record of achieving drug approvals in greater China, allows both Overland and its partners to benefit from each other’s respective strengths.
Therapeutic candidate programs across our portfolio are developed by our dedicated clinical and regulatory teams and other shared functional resources to achieve peak operational and capital efficiency.
We are committed to putting patients first and aim at fostering a culture of strong ethics and a high standard for quality.
We are launching a robust research and development engine of differentiated, novel therapeutics – all with the spirit and ambition of a nimble biotech.
Overland collaborates with innovative partners to jointly develop and strategically commercialize therapeutic programs for entry into Asia and expansion around the globe.
We accelerate the development of and access to promising new medicines for patients by sourcing the brightest talents and centralizing key operations.
Ed Zhang, MBA, serves as Co-founder and Interim CEO at Overland Pharmaceuticals, and Venture Partner, BioVenture at Hillhouse Capital.
Prior to Overland, Ed was VP of Corporate Development at Boston Pharmaceuticals, representing a new biotech business model focused on translational clinical development. As part of its founding team, Ed led corporate development and strategic initiatives including establishing partnerships with leading global pharma and biotech companies. Prior to joining Boston Pharma, Ed headed Global Business Development for Sanofi’s Renal Strategic Unit and was Director of Commercial Operations and Strategic Development at Genzyme before acquisition by Sanofi. Ed started his career as a medicinal chemist at Pharmacia & Upjohn and now brings over 17 years of biopharma industrial experience to Overland.
Ed holds an MBA from Kellogg School of Management at Northwestern University, an MS in chemistry from Binghamton University, and a BS from Nanjing University.
Dr. Luo serves as CDO, Head of Clinical and Preclinical Development of Overland Pharmaceuticals.
Prior to joining Overland, Dr. Luo worked for several biotechnology companies in China serving in various executive leadership positions with primary responsibilities including overseeing the global clinical development of target therapy and immunotherapy assets as well as overall portfolio management. In addition, Dr. Luo previously held multiple clinical development roles of increasing responsibility at major pharmaceutical companies including The Janssen Pharmaceutical Companies of Johnson & Johnson as well as at Daiichi Sankyo Pharma Development and Bristol-Myers Squibb. Dr. Luo brings to Overland over 20 years of industry experience in translational research and clinical development for innovative oncology, immunology and hematology therapeutics. he led and supported multiple NDA programs for novel oncology drugs, most notably Abivertinib, an EGFR inhibitor for lung cancer, Erdafitinib, a FGFR inhibitor for urothelial cancer, and Dasatinib, a BCR-ABL inhibitor for leukemia. Additionally, he engaged in the development of multiple biologic drugs including Cetuximab, Tigatuzumab, anti-VISTA antibody, anti-PD-1/Tim3 dual body, CD137 agonist and anti-CTLA4 antibody.
Dr. Luo completed his postdoctoral fellowship training at Cancer Institute of New Jersey. He received his Ph.D. in clinical pharmacology/cancer pharmacology from the University of North Carolina at Chapel Hill, his M.S. in biochemistry from Bowling Green State University, and his B.S. in chemistry from Peking University.
Jie Li serves as SVP, Head of Regulatory Affairs at Overland Pharmaceuticals.
Prior to Overland, Jie held different Regulatory Affairs positions at Pfizer China since 1999 and led the department from 2010 until April 2020. In this role, she supported all facets of Pfizer China’s pharma business for registration strategy of all new products including small and large molecule drugs, and vaccines, in addition to license maintenance of approved products. She proactively partnered with industry associations and government agencies to introduce international best practices into China for NMPA’s regulatory system reform. In addition to Pfizer, she has experience working at other MNCs, such as SmithKline Beecham China, BMS China and Wyeth. She has also served as the Co-Chair of Regulatory Affairs Working Group in RDPAC (R&D Based Pharmaceutical Association Committee) in China. Jie holds over 25 years of regulatory affairs experience covering multiple therapeutic areas including cardiovascular and metabolic disease, neuroscience, oncology, infectious disease, inflammation & immunology, rare disease, endocrinology, and vaccine.
Jie received her MS from Peking Union Medical Colleague and BS in Medicine from Beijing University of Traditional Chinese Medicine.
Dr. Jie Chen serves as SVP, Head of Biometrics at Overland Pharmaceuticals.
Prior to Overland, Dr. Chen was a distinguished scientist in biostatistics at Merck Research Laboratories (US). He previously worked in China as Senior Global Group Head of Biostatistics at Novartis and as Senior Director and Head of Biometrics & Information Sciences at AstraZeneca and Merck Serono. He is also a member of the China Tripartite Coordination Committee, responsible for drafting and revising technical guidance for drug development in China. Dr. Chen holds 25 years of experience in biopharmaceutical R&D and has been invited to present at FDA/industry statistics workshops, EMA statistics symposia, and numerous other venues.
Dr. Chen received his PhD in Statistics from Temple University, Philadelphia, and his MD degree from Shanghai Medical College, Fudan University.
Dr. Yi Feng serves as VP, Head of Oncology Clinical Science at Overland Pharmaceuticals.
Prior to Overland, Dr. Feng served as Senior Director of Oncology at Roche and led multiple successful registrational trials of Perjeta/Kadcyla/Herceptin SC/Tecentriq/Avastin for breast and gynecological cancers. Before joining Roche, Dr. Feng served as Associate Director at Merck Sharp & Dohme (MSD) working on Keytruda for gastric cancer, Therapeutic Area Lead for solid tumors at Janssen R&D working on Zytiga and Apalutamide for prostate cancer, and Medical Affair Manager at Novartis Oncology working on Ceritinib for non-small cell lung cancer. Previously, she also worked as Project Manager of Clinical Operations in oncology, diabetes mellitus, CVD, and nephrology for six years at Novartis, Sanofi-Aventis, and Novo Nordisk. Additionally, she worked at the Peking Union Medical College affiliated Hematology Hospital and Institute for seven years as a hematology physician and researcher before joining industry. Bringing over 15 years of industry experience, Dr. Feng has been actively involved in global and local registrational trials as well as successful NDA submissions in the US, EMA, and China.
Dr. Feng received her MS in Internal Medicine from Peking Union Medical College and her MD from Nanjing Medical University.
Dr. Weimin (Warren) Li serves as VP, Translational Medicine at Overland Pharmaceuticals.
Prior to Overland, Dr. Li was Translational Development Head, Cell Therapies at Takeda Pharmaceuticals leading translational and precision medicine strategies for Takeda’s cell therapy portfolio. Before Takeda, Dr. Li was a Director of Translational Medicine/Precision Medicine at AstraZeneca, where he led translational medicine, clinical biomarkers and diagnostics development for AZ’s immuno-oncology programs in gastrointestinal, genitourinary, and head & neck cancers. Prior to joining AstraZeneca, Weimin spent 10 years within the Oncology Translational Research group at Janssen Pharmaceuticals, where he led the transition from preclinical development to FIH of several IO assets. Weimin also led clinical biomarkers strategies for several full development programs, including abiraterone (anti-androgen), niraparib (PARPi) and trabectedin. Overall, Dr. Li brings over 18 years of experience in oncology drug development with a focus on translational medicine.
Dr. Li received his PhD from the University of Illinois at Urbana-Champaign and completed his postdoc training at the University of Chicago. He received his MS from Chinese Academy of Sciences and BS from Fudan University.
Julie ZHANG serves as VP, Head of Oncology Regulatory Affairs at Overland Pharmaceuticals.
Prior to Overland, Julie served as head of Rare disease, Hematology of Regulatory Affairs at Pfizer China and supported for registration strategy of the new products and license maintenance of approved products in these areas. Before joining Pfizer, she worked as RA Therapeutic Area lead at Sanofi China for Cardiovascular and Diabetes. Previously, she also worked at different positions in regulatory Affairs in some other multinational companies. She holds over 17 years of regulatory affairs experience covering multiple therapeutic areas including cardiovascular, metabolic disease, neuroscience, oncology, and rare disease.
Julie received her MBA from Université de Droit, d’économie et des Sciences d’Aix-Marseille and BS in Medicine from Beijing University of Traditional Chinese Medicine.
Kenneth Gao serves as VP of Alliance Management and Corporate Development at Overland Pharmaceuticals.
Prior to Overland, Kenneth most recently served as Senior Director of Corporate Development and Strategy as well as Head of China Operations at Assembly Biosciences. At Assembly Kenneth spearheaded establishment of Assembly China, led teams to execute strategic partnerships for assets in all development stages across the globe, and co-led multiple rounds of follow-on capital raising on Nasdaq. Before Assembly, he held various managerial positions in management consulting, transactions, and business operations at IMS Health, Eli Lilly, and Becton Dickinson. Kenneth also worked at Ennovance Capital, focused on mid-market private equity investments in the specialty chemical and pharmaceutical sectors.
Kenneth received an MBA in Health Sector Management from Duke University and a BS in Business Administration from State University of New York at Buffalo, NY.
Dr. Eric Hu serves as VP of Business Development at Overland Pharmaceuticals.
Prior to Overland, Dr. Hu was Senior Director of Business Development at Turning Point Therapeutics where he contributed to all aspects of strategic initiatives, deal sourcing, and diligence efforts. Before Turning Point Therapeutics, Dr. Hu spent over ten years at Gilead Sciences with increasing responsibilities from drug discovery to business development diligence. Dr. Hu is a coauthor of several high impact publications including Nature and Nature Medicine. Dr. Hu is also a key contributor and co-inventor of multiple clinical programs in antiviral, oncology, and inflammation including first-in-class long-acting HIV Capsid inhibitor Lenacapavir currently in multiple phase III clinical trials. Dr. Hu brings over 17 years of biopharmaceutical industry experience to Overland.
Dr. Hu received his Ph.D. in organic chemistry from University of California, Los Angeles, and BS from Beijing Normal University with honors.
ERIC KOO, MBA, B. Pharm, serves as CEO at Overland ADCT Biopharmaceuticals.
Prior to Overland ADCT, Eric was Vice President, Head of Oncology Business Unit at Takeda China focusing on multiple myeloma and lymphoma. Prior to joining Takeda, Eric served as Director, Oncology Business Unit and Director, Market Access, External Affairs & Key Account Management at Merck, Sharp and Dome (MSD) Taiwan. Prior to MSD, he served as Regional Marketing Director for APAC & Specialty Care BU Head, Malaysia/Singapore at Bayer APAC. Mr. Koo started his pharmaceutical career at Pfizer, spending 16 years in various sales, product management and marketing positions at both Pfizer Taiwan and Pfizer Emerging Market Asia & China, including 5 years as the China/APAC Regional Marketing Director for Oncology.
Mr. Koo earned his B. Pharmacy from Taipei Medical University and MBA from the University of North Carolina at Charlotte, Belk College of Business.
Dr. Shuyuan Yao serves as CEO of Allogene Overland Biopharm (PRC) Co., Ltd. from June 2021. Prior to Allogene Overland, he served as Chief Scientific Officer, Head of Research & Technology Development of Advanced Therapies Unit (ATU) at WuXi AppTec where he led new technology acquisition, development, translation and application. From May 2018, Dr. Yao served as the VP of Operations at WuXi AppTec and General Manager of WuXi ATU Co., Ltd, establishing the new subsidiary company, ATU China. At the start of his tenure at WuXi AppTec, he established and directed the Cell Therapy R&D business unit focusing on CAR-T cell therapy development from 2014. He oversaw the rollout of this business unit to create JW Therapeutics (Shanghai) Co., Ltd, a joint venture between WuXi AppTec and Juno Therapeutics, which was listed on the HKSE in Nov.2020, serving as VP of Operations.
Dr.Yao has established and managed several start-up projects and companies and has profound experiences in R&D, manufacturing, facility, team and project management. He started his pharmaceutical career at Sangamo Biosciences, later transitioning to various roles of increasing responsibility at Stemgent, CalCyte Therapeutics, and the Allen Institute for Brain Science. He was Associate Director of Biology at Vertex Pharmaceuticals R&D (Shanghai) Co., Ltd. before joining in WuXi AppTec.
Dr.Yao received his Ph.D. degree on Molecular & Medical Genetics from University of Toronto School of Medicine, accomplished postdoctoral training in stem biology at The Scripps Research Institute (TSRI). He graduated from Wuhan University,China.